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Background
Various viral vectors are being explored for use in vaccines
against diseases such as HIV, TB, and malaria. Although
unpredicted, the ''STEP'' trial results highlight the impor-
tance of safety assessments of candidate vaccines. Safety
parameters generally can not be measured directly, but
require indirect inference from the frequency of multiple
adverse events (AEs). We seek harmonization of AE assess-
ments to maximize their comparability and value across
trials of multiple vaccine candidates.
Methods
The Brighton Collaboration (BC) was created to develop
high quality information about vaccine safety; case defini-
tions on 24 AEs have been published. The BC formed the
Viral Vector Vaccines Safety Working Group (V3SWG) in
October, 2008. The BC secretariat organizes and supports
monthly conference calls.
Results
To date, the V3SWG has 1) recruited ~30 volunteers from
stakeholders representing academia, industry, and gov-
ernment for balance between virology and safety exper-
tise, 2) agreed on a standard template developed with
IAVI for collection of data on each vector and risk assess-
ment framework, and 3) developed a workplan to harmo-
nize assessment of the following issues: a) potential for
vector recombination with wild type pathogenic strains,
b) implications of prior infections on safety, c) genetic sta-
bility of replicating vaccine viruses in vivo, d) potential
changes of vaccine viral tropism, e) tests for absence of
reversion to virulence, f) absence of replication-compe-
tent virus when replication incompetent vectors are used,
g) vaccine effects on innate immunity and on the induc-
tion of an immuno-suppressive window or immune-acti-
vation, h) length of time for monitoring AEs, i) inclusion
of adventitious agents in cell culture, and j) possible sec-
ondary transmission of vaccine virus.
Conclusion
The BC has successfully launched the V3SWG as its first
entrée into harmonization of pre-licensure safety assess-
ments. The guidelines in development should improve
our ability to prioritize vector selection and interpret
safety data of viral vector vaccines.
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